For the fiscal period ending April 30, 2026, Alzamend Neuro is expected to report zero revenue and a consensus EPS loss of $0.67, with the stock currently trading at $1.33 against an average analyst price target of $28.00.
Investors are primarily focused on the clinical advancement of lead therapeutic candidates AL001 and ALZN002, alongside the company’s critical cash runway.
Recent developments include the initiation of a Phase II trial for AL001 in bipolar disorder patients, with full pharmacokinetics and pharmacodynamic data anticipated in August 2026. Management has cautioned that current cash reserves are insufficient to fund the next twelve months of operations, making capital raises or partnership news a top priority for shareholders.